FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma
FTL004 是一种抗 CD38 mAb，具有可忽略不计的红细胞结合和增强的促凋亡活性，是治疗多发性骨髓瘤和非霍奇金淋巴瘤的新型候选药物
期刊:Journal of Hematology & Oncology
影响因子:29.5
doi:10.1186/s13045-022-01395-0
Guangbing Zhang #, Cuiyu Guo #, Yan Wang #, Xianda Zhang #, Shuang Liu, Wen Qu, Chunxia Chen, Lingli Yan, Zhouning Yang, Zhixiong Zhang, Xiaohua Jiang, Xiaofeng Chen, Hong Liu, Qinhuai Lai, Xian Wei, Ying Lu, Shengyan Zhao, Han Deng, Yuxi Wang, Lin Yu, Hongbin Yu, Yu Wu, Zhaoming Su, Pengyu Chen, Zi
免疫
细胞生物学
淋巴瘤
骨髓瘤
红细胞
Apoptosis
